Fineotex Chemical Q2 FY27 Consolidated Revenue Soars 169% to ₹391.41 Cr
Fineotex Chemical's consolidated revenue for Q2 FY27 surged 169% to ₹391.41 crore. PAT grew 70.82% to ₹44.55 crore. For H1 FY27, revenue increased 166.81% to ₹778.13 crore, with PAT up 81.51% to ₹92.75 crore. ROIC stood at 36.12% and volumes grew 132.30%.
The substantial increase in revenue and profits, coupled with strong operational metrics like volume growth and ROIC, is expected to have a significant positive impact on the company's valuation and investor sentiment.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT for both the quarterly and half-yearly periods, indicating strong financial performance.
Fineotex Chemical Limited announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board of Directors, in their meeting on November 13, 2026, approved these results.
For the second quarter of FY27, consolidated total income from operations surged by 169.14% to ₹391.41 crore from ₹145.43 crore in the corresponding period of the previous year. Operating EBITDA increased by approximately 92.04% to ₹59.59 crore, and Profit After Tax (PAT) grew by 70.82% to ₹44.55 crore.
On a half-yearly basis, consolidated total income from operations rose by 166.81% to ₹778.13 crore. Operating EBITDA saw a significant increase of 111.22% to ₹118.74 crore, and PAT grew by 81.51% to ₹92.75 crore. The company also reported a consolidated Return on Invested Capital (ROIC) of approximately 36.12% for H1 FY27, with business volumes increasing by about 132.30% year-on-year.
The company also noted that the legal dispute concerning an Assignment Agreement for property under 'Assets Held for Sale' was ongoing as of September 30, 2026. A total advance of ₹1,008.00 lakhs was received as of this date.
What to do with a filing like this
Fineotex Chemical Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fineotex Chemical Limited. Read the original for the full detail.